Clinical Trial

Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated December 11, 2023 (before its estimated December 31, 2023 completion). Its status may not reflect the trial's current state.
Summary
In this study, the dose of methimazole was adjusted according to the different states of thyroid function, and the effects of conventional therapy and intensive therapy on the cumulative recurrence of Graves' hyperthyroidism after two years of drug withdrawal were evaluated. At the same time, the changes of immune indexes and inflammatory factors in the regulation process were evaluated. This study is a phase IV clinical study designed and carried out by the First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), which is a randomized, open and routine treatment group with parallel control.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-07-13; most recent amendment 2023-12-08.
Trial Details
NCT Number NCT05461820
Lead Sponsor The First Affiliated Hospital with Nanjing Medical University
Conditions Graves Disease, Relapse, Treatment, Drug Withdrawal
Enrollment 240 participants
Start Date 2018-05-01
Primary Completion 2023-12-31 (estimated)
Study Completion 2030-07-31 (estimated)
Updated on ClinicalTrials.gov 2023-12-11